亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose–response manner: a randomized, double-blind, placebo-controlled study

亮丙瑞林 医学 安慰剂 子宫内膜异位症 盆腔疼痛 可视模拟标度 曲普瑞林 不利影响 安慰剂对照研究 随机对照试验 泌尿科 内科学 麻醉 促黄体激素 促性腺激素释放激素 外科 激素 双盲 病理 替代医学
作者
Yutaka Osuga,Yoshifumi Seki,Masataka Tanimoto,Takeru Kusumoto,Kentarou Kudou,Naoki Terakawa
出处
期刊:Fertility and Sterility [Elsevier BV]
卷期号:115 (2): 397-405 被引量:58
标识
DOI:10.1016/j.fertnstert.2020.07.055
摘要

ObjectiveTo evaluate the efficacy and safety of three dose levels of relugolix, a gonadotropin-releasing hormone receptor antagonist, compared with placebo and leuprorelin in women with endometriosis-associated pain.DesignPhase 2, multicenter, randomized, double-blind, placebo-controlled study.SettingHospitals and clinics.Patient(s)Adult premenopausal women with endometriosis who had dysmenorrhea and endometriosis-associated pelvic pain.Intervention(s)During a 12-week treatment period, patients received relugolix 10 mg (n = 103), 20 mg (n = 100), or 40 mg (n = 103) as a daily oral dose; placebo (n = 97) as a daily oral dose; or leuprorelin 3.75 mg (n = 80) as a monthly subcutaneous injection.Main Outcome Measure(s)Primary endpoint was the change from baseline in mean visual analog scale score for pelvic pain during 28 days before the end of treatment.Result(s)The mean changes in mean visual analog scale score for pelvic pain were –3.8 mm in the placebo group; –6.2, –8.1, and –10.4 mm in the relugolix 10-mg, 20-mg, and 40-mg groups; respectively; and –10.6 mm in the leuprorelin group. The major adverse events with relugolix were hot flush, metrorrhagia, menorrhagia, and irregular menstruation, and bone mineral density decrease in a dose–response manner, which were also observed in the leuprorelin group with a frequency comparable with that in the relugolix 40-mg group.Conclusion(s)Oral administration of relugolix alleviated endometriosis-associated pain in a dose–response manner and was generally well tolerated. Relugolix 40 mg demonstrated efficacy and safety comparable with those of leuprorelin.Clinical Trial Registration NumberNCT01458301. To evaluate the efficacy and safety of three dose levels of relugolix, a gonadotropin-releasing hormone receptor antagonist, compared with placebo and leuprorelin in women with endometriosis-associated pain. Phase 2, multicenter, randomized, double-blind, placebo-controlled study. Hospitals and clinics. Adult premenopausal women with endometriosis who had dysmenorrhea and endometriosis-associated pelvic pain. During a 12-week treatment period, patients received relugolix 10 mg (n = 103), 20 mg (n = 100), or 40 mg (n = 103) as a daily oral dose; placebo (n = 97) as a daily oral dose; or leuprorelin 3.75 mg (n = 80) as a monthly subcutaneous injection. Primary endpoint was the change from baseline in mean visual analog scale score for pelvic pain during 28 days before the end of treatment. The mean changes in mean visual analog scale score for pelvic pain were –3.8 mm in the placebo group; –6.2, –8.1, and –10.4 mm in the relugolix 10-mg, 20-mg, and 40-mg groups; respectively; and –10.6 mm in the leuprorelin group. The major adverse events with relugolix were hot flush, metrorrhagia, menorrhagia, and irregular menstruation, and bone mineral density decrease in a dose–response manner, which were also observed in the leuprorelin group with a frequency comparable with that in the relugolix 40-mg group. Oral administration of relugolix alleviated endometriosis-associated pain in a dose–response manner and was generally well tolerated. Relugolix 40 mg demonstrated efficacy and safety comparable with those of leuprorelin.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
健壮的花瓣完成签到 ,获得积分10
2秒前
oywt发布了新的文献求助10
10秒前
霸气鞯完成签到 ,获得积分10
11秒前
11秒前
lf发布了新的文献求助10
14秒前
14秒前
15秒前
17秒前
bbdd2334发布了新的文献求助10
18秒前
19秒前
23秒前
李健的小迷弟应助bbdd2334采纳,获得10
25秒前
26秒前
忧伤的风华完成签到,获得积分10
32秒前
thanhvader999完成签到,获得积分10
32秒前
小乘号子发布了新的文献求助10
33秒前
量子星尘发布了新的文献求助10
34秒前
35秒前
小马甲应助科研通管家采纳,获得10
36秒前
36秒前
科研通AI2S应助科研通管家采纳,获得10
36秒前
36秒前
轻松的惜芹应助白日梦采纳,获得20
37秒前
38秒前
悦耳的沛岚完成签到,获得积分10
38秒前
41秒前
Xiaowen发布了新的文献求助10
41秒前
123发布了新的文献求助10
46秒前
学习使人头大完成签到 ,获得积分10
48秒前
jyy应助坚定灯泡采纳,获得10
50秒前
53秒前
3080完成签到 ,获得积分10
55秒前
小芭乐完成签到 ,获得积分10
56秒前
1分钟前
1分钟前
1分钟前
sunshihaoya发布了新的文献求助10
1分钟前
占那个完成签到 ,获得积分10
1分钟前
cos发布了新的文献求助10
1分钟前
Bond完成签到 ,获得积分10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976600
求助须知:如何正确求助?哪些是违规求助? 3520700
关于积分的说明 11204482
捐赠科研通 3257320
什么是DOI,文献DOI怎么找? 1798683
邀请新用户注册赠送积分活动 877881
科研通“疑难数据库(出版商)”最低求助积分说明 806613